CL2004000826A1 - Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 - Google Patents

Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129

Info

Publication number
CL2004000826A1
CL2004000826A1 CL200400826A CL2004000826A CL2004000826A1 CL 2004000826 A1 CL2004000826 A1 CL 2004000826A1 CL 200400826 A CL200400826 A CL 200400826A CL 2004000826 A CL2004000826 A CL 2004000826A CL 2004000826 A1 CL2004000826 A1 CL 2004000826A1
Authority
CL
Chile
Prior art keywords
agonist
piperazina
piridinil
trifluorometil
org
Prior art date
Application number
CL200400826A
Other languages
English (en)
Inventor
Mcmurray Wesley Dennis Gordon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33397006&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2004000826(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CL2004000826A1 publication Critical patent/CL2004000826A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
CL200400826A 2003-04-25 2004-04-16 Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 CL2004000826A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0309533 2003-04-25

Publications (1)

Publication Number Publication Date
CL2004000826A1 true CL2004000826A1 (es) 2005-03-04

Family

ID=33397006

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400826A CL2004000826A1 (es) 2003-04-25 2004-04-16 Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129

Country Status (13)

Country Link
EP (2) EP2277513A3 (es)
JP (2) JP2006524679A (es)
KR (3) KR20060006063A (es)
CN (1) CN1780612B (es)
AU (2) AU2004233745B2 (es)
BR (1) BRPI0409730A (es)
CA (2) CA2523379C (es)
CL (1) CL2004000826A1 (es)
MX (1) MXPA05011410A (es)
MY (1) MY142857A (es)
TW (1) TW200426142A (es)
WO (1) WO2004096196A2 (es)
ZA (1) ZA200507158B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5173190B2 (ja) * 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
CA2606064A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
CA2615209A1 (en) * 2005-08-01 2007-02-08 Pfizer Limited Mc4r-ag0nists for the treatment of urinary tract dysfunction
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
JPWO2008007664A1 (ja) 2006-07-11 2009-12-10 武田薬品工業株式会社 二環性複素環化合物およびその用途
EP2123644B1 (en) 2007-03-07 2014-12-17 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
WO2009063991A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited ピリドオキサゼピン誘導体およびその用途
US20100266504A1 (en) * 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
WO2009063993A1 (ja) * 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
MY157497A (en) 2009-06-15 2016-06-15 Takeda Pharmaceutical Pyrazinooxazepine derivatives
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
WO2012002583A1 (en) * 2010-07-02 2012-01-05 Vanderbilt University Method for treating schizophrenia and related diseases with a combination therapy
EP2824106B1 (en) 2012-03-06 2016-11-23 Takeda Pharmaceutical Company Limited Tricyclic compound
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
CA2044854A1 (en) 1990-07-19 1992-01-20 Hong-I Chen Method for preventing or treating urinary incontinence
EP0572863A1 (de) 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
TW270114B (es) 1993-10-22 1996-02-11 Hoffmann La Roche
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria
AU5343298A (en) 1997-01-13 1998-08-03 Yamanouchi Pharmaceutical Co., Ltd. 5-ht2c receptor agonists and aminoalkylindazole derivatives
WO1998033504A1 (en) * 1997-02-03 1998-08-06 Akzo Nobel N.V. Treatment of urinary incontinence
EP0863136B1 (en) 1997-02-25 2003-09-24 Akzo Nobel N.V. Derivatives of azetidine and pyrrolidine
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU727654B2 (en) 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative
RU2198873C2 (ru) * 1998-02-26 2003-02-20 Акцо Нобель Н.В. Производные азетидина и пирролидина
WO1999058490A2 (en) 1998-05-08 1999-11-18 Akzo Nobel N.V. Novel aryl-hydro naphthalenal kanamines
GB9819035D0 (en) 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819019D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819032D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds IV
GB9819033D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
GB9819020D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds III
GB9820767D0 (en) 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
WO2000028993A1 (en) 1998-11-19 2000-05-25 Nortran Pharmaceuticals, Inc. Serotonin ligands as pro-erectile compounds
EA200100671A1 (ru) 1998-12-17 2001-12-24 Американ Хоум Продактс Корпорейшн ПРОИЗВОДНЫЕ 2,3,4,4a-ТЕТРАГИДРО-1H-ПИРАЗИНО [1,2a]ХИНОКСАЛИН-5(6H)-ОНА, ЯВЛЯЮЩИЕСЯ АГОНИСТАМИ 5HT2C
AU2619800A (en) 1999-01-27 2000-08-18 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
AU4856600A (en) 1999-05-18 2000-12-05 Synaptic Pharmaceutical Corporation Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
US6465467B1 (en) * 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
DE60024986T2 (de) * 1999-05-21 2006-07-27 Biovitrum Ab Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung
SE9901884D0 (sv) * 1999-05-21 1999-05-21 Pharmacia & Upjohn Ab Novel compounds their use and preparation
US6552017B1 (en) 1999-06-15 2003-04-22 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
GB9918962D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
GB9918965D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20030004207A1 (en) 1999-11-29 2003-01-02 Douglas A. Craig Use of compounds which activate a 5-ht receptor to treat urinary incontinence
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
JP2003529569A (ja) 2000-03-14 2003-10-07 ファルマシア・アンド・アップジョン・カンパニー 新規な２，３，４，５−テトラヒドロ−１Ｈ−［１，４］ジアゼピノ［１，７−ａ］インドール化合物
WO2001083487A1 (fr) 2000-04-28 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derive de froindazole
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
PL360982A1 (en) * 2000-11-20 2004-09-20 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
NZ525700A (en) * 2000-11-20 2004-12-24 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
US6498184B2 (en) * 2000-12-05 2002-12-24 Akzo Nobel N.V. Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
CA2432181C (en) 2000-12-20 2009-11-17 Bristol-Myers Squibb Company Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
RU2003121304A (ru) 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
CA2432085C (en) 2000-12-27 2009-02-24 F. Hoffmann-La Roche Ag Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
WO2002074746A1 (fr) 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Derives de benzazepine
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
EP1404679A2 (en) 2001-07-05 2004-04-07 PHARMACIA & UPJOHN COMPANY (hetero)aryl substituted benzofurans as 5-ht ligands
MXPA04001202A (es) 2001-08-06 2005-02-17 Pharmacia & Upjhon Company Ligandos tetraciclicos terapeuticamente utiles.
JP2005526691A (ja) 2001-08-08 2005-09-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 治療剤１Ｈ−ピリド［４，３−ｂ］インドール
CA2460126A1 (en) 2001-09-21 2003-03-27 Pharmacia & Upjohn Company Tricyclic indole derivatives as 5-ht ligands
BR0213417A (pt) * 2001-10-18 2004-11-03 Upjohn Co Compostos e composições de tetraciclicazaindóis e indolinas tendo atividade de 5-ht e seus usos
AU2002360819A1 (en) 2001-12-28 2003-07-24 Bayer Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
AU2002367323A1 (en) 2001-12-28 2003-07-24 Bayer Pharmaceuticals Corporation Benzothieno (3,2-
JP2005516964A (ja) 2001-12-28 2005-06-09 バイエル・フアーマシユーチカルズ・コーポレーシヨン ５−ｈｔ２ｃレセプターと関連する疾患における使用のための１ｈ−ピラゾリル誘導体化合物
AU2002364035A1 (en) 2001-12-28 2003-07-24 Bayer Pharmaceuticals Corporation 4-sulfide / sulfoxide / sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
CA2485537A1 (en) 2002-06-19 2003-12-31 Biovitrum Ab Novel compounds, their use and preparation

Also Published As

Publication number Publication date
WO2004096196A2 (en) 2004-11-11
CA2670067A1 (en) 2004-11-11
AU2010203093A1 (en) 2010-08-12
CA2523379C (en) 2010-06-22
BRPI0409730A (pt) 2006-05-09
MY142857A (en) 2011-01-14
KR20070108921A (ko) 2007-11-13
AU2004233745B2 (en) 2010-03-25
TW200426142A (en) 2004-12-01
CN1780612B (zh) 2010-12-01
AU2004233745A1 (en) 2004-11-11
ZA200507158B (en) 2006-11-29
KR20100103726A (ko) 2010-09-27
CN1780612A (zh) 2006-05-31
KR20060006063A (ko) 2006-01-18
CA2523379A1 (en) 2004-11-11
EP2277513A2 (en) 2011-01-26
EP1620081A2 (en) 2006-02-01
EP2277513A3 (en) 2011-09-07
JP2011064695A (ja) 2011-03-31
MXPA05011410A (es) 2005-12-12
WO2004096196A3 (en) 2005-03-10
JP2006524679A (ja) 2006-11-02

Similar Documents

Publication Publication Date Title
CL2004000826A1 (es) Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
ECSP088461A (es) Composiciones farmacéuticas que contienen buprenorfina
WO2004087758A3 (en) Il 13 receptor alpha 2 antibody and methods of use
BRPI0415505A (pt) agente terapêutico para mesotelioma
BRPI0514474A (pt) multiparticulados
EP1546923A4 (en) METADATA INDEX STRUCTURE, METADATA INDEX REALIZATION METHOD, AND METADATA SEARCH METHOD USING THE METADATA INDEX
AR028505A1 (es) Utilizacion de un antagonista de los receptores de cannabinoides centrales para la preparacion de medicamentos utiles para que sea mas frcil detener el consumo de tabaco
ZA200604791B (en) Hydronopol derivatives as agonists on human ORL1 receptors
CL2004000643A1 (es) Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana.
BRPI0816553A2 (pt) "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
SV2006002245A (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos ref. p-sv-78.797/msu
BRPI0710232B8 (pt) composto antagonista do receptor de il-8, composição farmacêutica que compreende o dito composto e uso do mesmo para o tratamento de uma doença mediada por quimiocina
AR063640A1 (es) Anticuerpos agonistas de trkb y usos de los mismos
CR10481A (es) Equipo, sistemas y metodos para confirmar el uso de un dispositivo oral
UY31502A1 (es) Proceso mejorado para sintetizar 5-cyclopentyl-5-11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ol usando tmeda
BRPI0717496A2 (pt) Polímeros ramificados e métodos para sua síntese e uso
CL2007003841A1 (es) Compuestos derivados de 4(5h-1 lambda-tiazol-2-il)piperidina; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar diabetes.
ZA200607872B (en) Novel beta agonists, method for producing the same and their use as drugs
UY29109A1 (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios
BR0108549B1 (pt) dispositivo para eliminar as aparas dianteiras e de extremidade de uma série de rolos e para selecionar os rolos.
AU2003218660A8 (en) Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds
BRPI0403991A (pt) Composição útil para a produção de uma espuma de poliuretano
CL2007003422A1 (es) Uso de un antagonista de la proteina pik3r3 para inhibir el crecimiento de un glioma que expresa dicha proteina; y metodo para diagnosticar la presencia de un glioma en un mamifero.
BR0215064A (pt) Agonistas receptores seletivos de dopamina d3 para o tratamento de disfunção sexual
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h